PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma.
PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma.
复制标题
DOI：
10.1158/0008-5472.can-08-1154
复制
发表时间：
2008-07-15
期刊：
影响因子：
11.2
通讯作者：
Sherman ME
中科院分区：
文献类型：
--
作者：
Lacey JV Jr;Mutter GL;Ronnett BM;Ioffe OB;Duggan MA;Rush BB;Glass AG;Richesson DA;Chatterjee N;Langholz B;Sherman ME
抑癌基因PTEN的失活在子宫内膜癌及其前体子宫内膜不典型增生（EH）中普遍存在。我们通过免疫组化（IHC）比较了138例诊断为EH的子宫内膜活检组织中PTEN的表达，这些患者被诊断为EH，然后至少在1年后（中位数，6年）被诊断为子宫内膜癌，241例单独匹配的对照组被诊断为EH，但在同等随访期间没有进展为癌。我们评估了原发性高血压患者活检组织中的PTEN状态（正常与无效），以估计25年后发生子宫内膜癌的相对风险（RR）。对115例病例和193例对照的分析显示，40%的病例和44%的对照的索引活检组织中存在PTEN缺失的腺体（P=0.85; RR=1.51，95%CI，0.73-3.13）。对于预测进展为癌，PTEN-空状态具有低敏感性（44%，95%CI，45%-54%）和特异性（51%，95%CI，44%-58%）。在105例索引活检和癌的PTEN结果中，16%具有PTEN无效索引活检，23%具有PTEN无效癌，26%具有PTEN无效索引活检和癌。子宫内膜活检组织中PTEN的缺失与子宫内膜癌的进展无关，也不是子宫内膜癌进展的敏感和特异性标志物。
Inactivation of PTEN tumor suppressor gene is common in endometrial carcinoma and its precursor, atypical endometrial hyperplasia (EH). We compared PTEN expression via immunohistochemistry (IHC) in endometrial biopsies diagnosed as EH in 138 cases, who were diagnosed with EH and then endometrial carcinoma at least 1 year later (median, 6 years), and 241 individually matched controls, who were diagnosed with EH but did not progress to carcinoma during equivalent follow-up. We assessed PTEN status (normal vs. null) in index biopsies containing EH to estimate the relative risk (RR) of developing endometrial carcinoma up to 25 years later. Analysis of 115 cases and 193 controls with satisfactory assays revealed PTEN-null glands in index biopsies of 40% of cases and 44% of controls (P=0.85; RR=1.51, 95% CI, 0.73-3.13). For predicting progression to carcinoma, PTEN-null status had low sensitivity (44%, 95% CI, 45%-54%) and specificity (51%, 95% CI, 44%-58%). Among 105 cases with PTEN results for both index biopsy and carcinoma, 16% had a PTEN-null index biopsy, 23% had PTEN-null carcinoma, and 26% had both a PTEN-null index biopsy and carcinoma. Loss of PTEN in endometrial biopsies was neither associated with nor a sensitive and specific marker of subsequent progression to endometrial carcinoma.